Genotypic Resistance Remains A Concern In Chronic Hepatitis B Patients With High Viral Load After Lamivudine And Adefovir Combination Therapy

References

• Sarin SK, Kumar M, Lau GK, et al Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98.
   PubMed Web of Science ®Google Scholar
• Cai SH, Lu SX, Liu LL, Zhang CZ, Yun JP. Increased expression of hepatocyte nuclear factor 4 alpha transcribed by promoter 2 indicates a poor prognosis in hepatocellular carcinoma. Therap Adv Gastroenterol. 2017;10:761–771. doi:10.1177/1756283X17725998
   PubMed Web of Science ®Google Scholar
• Ou H, Cai S, Liu Y, Xia M, Peng J. A noninvasive diagnostic model to assess nonalcoholic hepatic steatosis in patients with chronic hepatitis B. Therap Adv Gastroenterol. 2017;10:207–217. doi:10.1177/1756283X16681707
   PubMed Web of Science ®Google Scholar
• Liaw YF, Gane E, Leung N, et al 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486–495. doi:10.1053/j.gastro.2008.10.02619027013
   PubMed Web of Science ®Google Scholar
• Yu MW, Chang HC, Chen PJ, et al Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan. Int J Epidemiol. 2002;31:1008–1015. doi:10.1093/ije/31.5.100812435776
   PubMed Web of Science ®Google Scholar
• Wu X, Cai S, Li Z, et al Potential effects of telbivudine and entecavir on renal function: a systematic review and meta-analysis. Virol J. 2016;13:64. doi:10.1186/s12985-016-0522-627062520
   PubMed Web of Science ®Google Scholar
• Xue X, Cai S. Comment on “Assessment of liver stiffness in pediatric fontan patients using transient elastography”. Can J Gastroenterol Hepatol. 2016;2016:9343960. doi:10.1155/2016/934396028025635
   PubMed Web of Science ®Google Scholar
• Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–283. doi:10.1002/hep.2815626566064
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–398. doi:10.1016/j.jhep.2017.03.02128427875
   PubMed Web of Science ®Google Scholar
• Al AH, Peedikayil MC, Al QM, et al HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: a randomized controlled study. Saudi J Gastroenterol. 2017;23:190–198.28611343
   PubMed Web of Science ®Google Scholar
• Bertuccio P, Turati F, Carioli G, et al Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017;67:302–309. doi:10.1016/j.jhep.2017.03.01128336466
   PubMed Web of Science ®Google Scholar
• Cai S, Yu T, Jiang Y, Zhang Y, Lv F, Peng J. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result. Clin Exp Med. 2016;16:429–436. doi:10.1007/s10238-015-0373-226164128
   PubMed Web of Science ®Google Scholar
• Xue X, Cai S, Ou H, Zheng C, Wu X. Health-related quality of life in patients with chronic hepatitis B during antiviral treatment and off-treatment. Patient Prefer Adherence. 2017;11:85–93. doi:10.2147/PPA.S12713928138226
   PubMed Web of Science ®Google Scholar
• Zeng J, Cai S, Liu J, Xue X, Wu X, Zheng C. Dynamic changes in liver stiffness measured by transient elastography predict clinical outcomes among patients with chronic hepatitis B. J Ultrasound Med. 2017;36:261–268. doi:10.7863/ultra.15.1205427914175
   PubMed Web of Science ®Google Scholar
• Hu Y, Xu C, Xu B, et al. Safety and efficacy of telbivudine in late pregnancy to prevent mother-to-child transmission of hepatitis B virus: a multicenter prospective cohort study. J Viral Hepat. 2018;25:429–437. doi:10.1111/jvh.1283429193547
   PubMed Web of Science ®Google Scholar
• Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–686. doi:10.1053/j.gastro.2005.11.01616530509
   PubMed Web of Science ®Google Scholar
• Kurokawa M, Hiramatsu N, Oze T, et al Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection. J Gastroenterol. 2012;47:577–585. doi:10.1007/s00535-011-0522-722231575
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662. doi:10.1002/hep.2319019714720
   PubMed Web of Science ®Google Scholar
• Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–2219. doi:10.1016/j.vaccine.2011.12.11622273662
   PubMed Web of Science ®Google Scholar
• Cai SH, Lv FF, Zhang YH, Jiang YG, Peng J. Dynamic comparison between Daan real-time PCR and Cobas TaqMan for quantification of HBV DNA levels in patients with CHB. BMC Infect Dis. 2014;14:85. doi:10.1186/1471-2334-14-8524528480
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185. doi:10.1016/j.jhep.2012.02.01022436845
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236. doi:10.1016/j.jhep.2018.03.01929628281
   PubMed Web of Science ®Google Scholar
• Chen CJ, Yang HI, Su J, et al Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73. doi:10.1001/jama.295.1.6516391218
   PubMed Web of Science ®Google Scholar
• Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis. 2006;26:142–152. doi:10.1055/s-2006-93975216673292
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–1127. doi:10.1056/NEJMra100168321992124
   PubMed Web of Science ®Google Scholar
• Chinese Society of Hepatology CMA, Chinese Society of Infectious Diseases CM. The guideline of prevention and treatment for chronic hepatitis B:a 2015 update. Chin J Hepatol. 2015;23:888–905. doi:10.3760/cma.j.issn.1007-3418.2015.12.002
   Google Scholar
• Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol. 2011;106:1264–1271. doi:10.1038/ajg.2011.4521364549
   PubMed Web of Science ®Google Scholar
• Cai S, Cao J, Yu T, Xia M, Peng J. Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine. Medicine (Baltimore). 2017;96:e7021. doi:10.1097/MD.000000000000702128562554
   PubMed Web of Science ®Google Scholar
• Zheng C, Yan H, Zeng J, Cai S, Wu X. Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B. Infect Drug Resist. 2019;12:845–854. doi:10.2147/IDR.S19514431114265
   PubMed Web of Science ®Google Scholar
• Cai S, Li Z, Yu T, Xia M, Peng J. Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs. Infect Drug Resist. 2018;11:469–477. doi:10.2147/IDR.S16303829662321
   PubMed Web of Science ®Google Scholar
• Liu F, Wang X, Wei F, et al Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis. Virol J. 2014;11:59. doi:10.1186/1743-422X-11-5924673792
   PubMed Web of Science ®Google Scholar
• Veenstra DL, Sullivan SD, Clarke L, et al Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 2007;25:963–977. doi:10.2165/00019053-200725110-0000617960954
   PubMed Web of Science ®Google Scholar